ADVM Adverum Biotechnologies Inc.

5.98
+0.33  (+6%)
Previous Close 5.65
Open 5.6
Price To Book 1.88
Market Cap 377942034
Shares 63,201,009
Volume 623,179
Short Ratio
Av. Daily Volume 488,312

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be discontinued - noted November 1, 2018.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)
Phase 1 24-Week data from first cohort due 2H 2019.
ADVM-022
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO
  2. Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO
  3. Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD
  4. What Kind Of Shareholders Own Adverum Biotechnologies, Inc. (NASDAQ:ADVM)?
  5. Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer
  6. Adverum Biotechnologies to Participate in Upcoming Conferences
  7. Adverum Biotechnologies (ADVM) Upgraded to Buy: What Does It Mean for the Stock?
  8. Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
  9. Adverum to Present at the Cowen 39th Annual Health Care Conference
  10. Adverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  11. Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference
  12. Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals — Future Expectations, Projections Moving into 2019
  13. Adverum Biotechnologies Provides 2019 Outlook
  14. Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference
  15. What Bargains? Play 5 Stocks With Rising P/E Instead
  16. Is Adverum Biotechnologies, Inc. (ADVM) A Good Stock To Buy?
  17. Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
  18. Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
  19. Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
  20. Adverum to Present at 30th Annual Piper Jaffray Healthcare Conference